Synchron has high hopes that after successfully implanting the first minimally invasive neural brain-computer interface device in a human, it will eventually be able to give a "voice" to patients, including paralyzed individuals, who are unable to communicate. The company is conducting clinical trials and is hoping to use the data to apply for US FDA approval of the Stentrode device.

The company launched in Silicon Valley on April 21 with plans to develop a device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.

The company launched in Silicon Valley on April 21 with plans to develop a device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.

At this year’s International Stroke Conference, manufacturers offered a glimpse of new and emerging technologies for both ischemic and hemorrhagic stroke. These neurointerventional devices are gaining momentum and driving growth in the market for stroke products, a largely un-penetrated market valued at more than $1 billion worldwide.